EASY BIOInc (353810) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of EASY BIOInc stock KRW 14,700, price KRW 4,900, upside +200.0%, quality 62 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 2,737 KRW – 8,060 KRW · fair‑value band 8,780 KRW – 21,488 KRW · the 4,900 KRW price screens below the 14,700 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow EASY BIOInc in your weekly email
Every Wednesday you see whether EASY BIOInc is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EASY BIO,Inc. provides specialized piglet feed and feed additives solutions in South Korea and internationally. The company was founded in 2020 and is based in Seoul, South Korea.
Stock analysis
EASY BIOInc (353810) currently trades at 4,900 KRW, while our model-based Fair Value estimate is 14,700 KRW, implying the stock looks roughly 67% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 35,010 KRW per share, and 23 of the 26 models we run sit above the 4,900 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,882 KRW, and 3 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 8,780 KRW (bear) to 21,488 KRW (bull), the price of 4,900 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Consumer Non-Cyclicals sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
EASY BIOInc reported revenue of 477B KRW in FY2025 versus 129B KRW in FY2021, a compound +38.5%/yr. Reported net income was 27.8B KRW in FY2025, compounding +26.4%/yr from FY2021.
Key figures
Market cap 162B KRW (≈ $121M) Micro · P/S ratio 1.19 · Dividend yield 3.6% · Net margin 6.3% · Return on equity 2,788% · Return on assets (EBIT) 11.7% (5-year average) · Operating margin 10.7% · Revenue growth (YoY) +23.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −27% fair-value upside, at 200%, 353810 screens cheaper than that median.
Fair Value models
Bear8,780 KRWFair Value 14,700 KRWBull21,488 KRW
Price 4,900 KRW · Upside +200.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+24.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.5%
Dividend (yield on the price)3.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 9%
2025 sits 84% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +0.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Food & Tobacco · 27 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+200.0% · Top 25%
Profitability
Return on assets8.5% · Top 25%
Net margin (12 months)6.3% · Above median
Operating margin (12 months)10.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)23.5% · Top 25%
Dividend yield (12 months)3.6% · Above median
Balance sheet
Debt / equity0.63× · Highest 25%
Valuation Multiplesvs Food & Tobacco median · lower = cheaper
P/B1.51× · Pricier than median
P/S (12 months)1.08× · Priciest 25%
Price / free cash flow (fiscal year)5.7× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EASY BIOInc Fair Value". https://www.fairvalue-calculator.com/stock/353810
Frequently asked questions
Is EASY BIOInc (353810) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 14,700 KRW versus a price of 4,900 KRW, about +200% upside (undervalued).
What is the fair value of 353810?
Our model-based fair value for EASY BIOInc is 14,700 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 4,900 KRW.
What is the quality score of 353810?
EASY BIOInc has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EASY BIOInc (353810)?
Our model-based price target is the fair value of 14,700 KRW (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 8,780 KRW, optimistic scenario 21,488 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the EASY BIOInc stock forecast for 2026?
Our models put fair value at 14,700 KRW, about +200% upside versus a price of 4,900 KRW (undervalued). Cautious scenario 8,780 KRW, optimistic scenario 21,488 KRW. The calculation is refreshed regularly with new filings.
Does EASY BIOInc pay a dividend?
EASY BIOInc currently shows a dividend yield of 3.62% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of EASY BIOInc (353810)?
EASY BIOInc has a dividend yield of 3.6%. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into EASY BIOInc (353810)?
For today's price to be fair in a discounted-cash-flow model, EASY BIOInc would have to grow free cash flow by +2.3 % per year for five years (discount rate 13.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +40.2 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 353810 use?
Our models discount EASY BIOInc at 13.6 %: a base by market capitalisation (micro), damped by beta 1.14, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For EASY BIOInc that is +2.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.6 %) and the same formula as our fair value.
How much growth has EASY BIOInc (353810) delivered so far?
Over the past 5 years revenue at EASY BIOInc grew +40.2 % a year. The price currently implies free-cash-flow growth of +2.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of EASY BIOInc (353810) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into EASY BIOInc (+2.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of EASY BIOInc (353810)?
The free-cash-flow yield on the price is 17.49 %: that much free cash flow EASY BIOInc produces per unit of market value. When it exceeds the discount rate of our models (13.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of EASY BIOInc (353810)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EASY BIOInc it is 14,700 KRW per share (as of Nov 8, 2026), against a price of 4,900 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is EASY BIOInc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 353810 trades below its calculated fair value: price 4,900 KRW, fair value 14,700 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 353810?
No. The price is what the market pays today (4,900 KRW); the fair value is what the company's own numbers justify (14,700 KRW). For EASY BIOInc the two are 9,800 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is EASY BIOInc worth?
The market values EASY BIOInc at about 162B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 4,900 KRW; our models calculate a fair value of 14,700 KRW per share.
What do the bullish and bearish scenarios say about 353810?
Our models span a range for EASY BIOInc: cautious scenario 8,780 KRW, base 14,700 KRW, optimistic 21,488 KRW per share (as of Nov 8, 2026, price 4,900 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EASY BIOInc (353810)?
Balance-sheet figures for EASY BIOInc (as of Nov 8, 2026): debt of 0.63 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is 353810 from its 52-week high?
EASY BIOInc trades at 4,900 KRW, about 39% below its 52-week high of 8,060 KRW and at the low of 4,900 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 14,700 KRW is for.
Which stocks are comparable to EASY BIOInc?
From the same area (Consumer Non-Cyclicals) we also value FB, URC, MONDE, CNPF, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EASY BIOInc stock attractive at the current price?
The data as of Nov 8, 2026: price 4,900 KRW, calculated fair value 14,700 KRW (+200%), Quality Score 62/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 353810 calculated?
We run EASY BIOInc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 14,700 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. EASY BIOInc currently trades 67% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EASY BIOInc (353810)?
The closing price on Nov 9, 2026 was 4,900 KRW. Our model-based fair value is 14,700 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EASY BIOInc right now?
The price is below even our cautious bear case (8,780 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (8,780 KRW to 21,488 KRW) leaves room in how you read the outcome.
Key figures of EASY BIOInc
How large is the market capitalisation of EASY BIOInc (353810)?
The market capitalisation of EASY BIOInc is 162B KRW (≈ $121M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EASY BIOInc (353810)?
The price-to-sales ratio of EASY BIOInc is 1.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of EASY BIOInc (353810)?
The dividend yield of EASY BIOInc is 3.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of EASY BIOInc (353810)?
The net margin of EASY BIOInc is 6.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EASY BIOInc (353810)?
The return on equity (ROE) of EASY BIOInc is 2,788% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EASY BIOInc (353810)?
On an EBIT basis the return on assets of EASY BIOInc is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EASY BIOInc (353810)?
The operating margin of EASY BIOInc is 10.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EASY BIOInc (353810)?
Revenue at EASY BIOInc is growing +23.5% versus a year earlier (3y avg +45.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at EASY BIOInc (353810)?
Earnings per share at EASY BIOInc are growing −6.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does EASY BIOInc (353810) carry?
The net debt of EASY BIOInc is 91.4B KRW (fiscal year 2025, ≈ 3.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch EASY BIOInc in the live analysis
One click puts EASY BIOInc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026